Reversal of the Antithrombotic Action of New Oral Anticoagulants
Status:
Unknown status
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The main goal of this study is to improve safety and efficiency of clinical practice with the
new generation of oral anticoagulants.
1. To determine the effect of new oral anticoagulants (dabigatran and rivaroxaban) on
platelets and coagulation mechanisms under flow conditions.
2. To evaluate the ability of the concentrates containing coagulation factors (PCCs and
FVIIa) to reverse the effects induced by the new anticoagulants.
These studies will be carried out ex vivo in blood samples obtained from healthy volunteers
undergoing oral anticoagulant therapy at doses of proven efficacy and safety used in previous
clinical trials.